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long-acting injectable risperidone. METHODS: Retrospective analysis (Jan 2006-
Dec 2008) of Texas Medicaid data was conducted for patients  18 years old with
schizophrenia (ICD-9: 295.xx). Patients who initiated either oral (oral cohort) or
injectable risperidone (injectable cohort), had no prior risperidone for at least 12
months, and had at least one additional prescription following initiation were
included. Medical care services and costs were compared within and between co-
horts for 12months pre- and post-initiation using paired-, independent t-tests and
McNemar tests. RESULTS: 1544 patients were included (oral cohort: n1261, mean
age  38yrs, 54% male; injectable cohort: n283, mean age39yrs, 61% male). The
injectable cohort (4.6, SD2.9) had a significantly higher mean Chronic Disease
Score (CDS) compared to the oral cohort (3.2, SD2.9) (p0.05). The percent of
patients with at least one psychiatric-related hospitalization significantly de-
creased by 10.6% in the injectable cohort (25.0% to 14.5%; p0.05) compared to 6.1%
in the oral cohort (18.7% to 12.6%; p0.05), and average hospital length of stay (LOS)
was significantly reduced by 2.5 days (4.4 to 1.9 days) versus 0.9 days (2.6 to 1.7
days), respectively (p0.05). Direct mental health-related medical costs signifi-
cantly decreased by $1395 ($4968 to $3573; p0.05) in the injectable cohort com-
pared to $51 in the oral cohort ($1912 to $1861; NS) (p0.05). CONCLUSIONS: For
patients initiated on long-acting injectable risperidone, clinical utilization and eco-
nomic outcomes improved one year post-initiation, as the number hospitaliza-
tions, LOS, and total mental health-related medical costs decreased. While inject-
able cohort patients may be a sicker population (as evidenced by higher CDS and
higher levels of baseline and follow-uputilization and costs), their level of improve-
ment was higher than that of the oral cohort.
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FACTORS ASSOCIATED WITH HEALTHCARE COSTS IN A POPULATION OF
COMMERCIALLY INSURED CHILDREN AND ADOLESCENTS WITH ATTENTION
DEFICIT/HYPERACTIVITY DISORDER AND PSYCHIATRIC COMORBIDITIES
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OBJECTIVES: Previous evidence has demonstrated that the presence of psychiatric
comorbidities in patients with ADHD is associated with increased total healthcare
costs. This study examined factors associated with healthcare costs in a commer-
cially-insured population with ADHD and 1 psychiatric comorbidity.METHODS:
Using the Market Scan database (2005–2007), we examined claims for 4,613 com-
mercially-insured patients ages 6 to 17 years with a diagnosis of ADHD (ICD-9:
314.xx) and 1 of the following psychiatric comorbidities: oppositional defiant
disorder, conduct disorder, learning disability, anxiety disorder, and depression.
Percent of days covered (PDC) by 1 ADHD medication was calculated for the
12-month period following index date. The population was divided into two
groups: consistent users (PDC70%) or inconsistent users (PDC70%). Chi-square
tests for categorical variables and t-test or ANOVA for continuous variables were
employed to identify differences between the groups (significant when P0.05).
Generalized linearmodels with gamma-distributed error and log-link were used to
evaluate the association between total healthcare costs and covariates that in-
cluded patient demographics, each comorbidity, and treatment-consistency.
RESULTS: The study population was predominantly male (64.8%), had a mean age
of 12.6 years, and was predominantly urban (87.3%). In specifying the regression
model, the following covariates were significantly associated with the cost out-
come: treatment-consistency, age, gender, insurance type, index year, and each of
the tested psychiatric comorbidities. Relative to consistent users, inconsistent us-
ers had lowermodeled total healthcare costs (P0.0001). Female sex, increased age,
and each of the psychiatric comorbidities were associated with increased total
healthcare cost relative to their counterpartswithout those attributes (P0.0087 for
female sex; P0.0001 for all other covariates). CONCLUSIONS: In the studied pop-
ulation of children and adolescents with ADHD and concurrent mental health
diagnoses, after controlling for significant covariates, inconsistent use of ADHD
medications was associated with lower total healthcare costs than consistent use.
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THE COST-EFFECTIVENESS OF GUANFACINE EXTENDED RELEASE (GXR) VERSUS
ATOMOXETINE (ATX) FOR THE TREATMENT OF ATTENTION-DEFICIT/
HYPERACTIVITY DISORDER (ADHD) IN CHILDREN AND ADOLESCENTS
Erder M1, Chen K2, Wu EQ2, Hodgkins P1, Sikirica V1
1Shire Pharmaceuticals, Wayne, PA, USA, 2Analysis Group, Inc., Boston, MA, USA
OBJECTIVES:To evaluate the cost-effectiveness of GXR vs. ATX for the treatment of
ADHD in children and adolescents from a US third-party payer perspective.
METHODS:Aneconomicmodelwas developed to estimate the cost effectiveness of
GXR vs. ATX during a 4-week drug titration period and a 48-week maintenance
period (one-year time horizon). Effectiveness was measured by the number of re-
sponders (defined as patients with 25% reduction in ADHD-Rating Scale-IV total
observed score compared to baseline), and estimated quality-adjusted life years
(QALYs). The model assumed all patients received treatment until the end of titra-
tion and only responders continued treatment afterwards. A uniform constant
discontinuation rate, based on the long-term trials of GXR and ATX, was applied.
Response rates were obtained from a matching-adjusted indirect comparison of
efficacy between GXR and ATX based on the Phase III trials. Published utilities
corresponding to response and non-response health states were applied. Disutility
due to adverse events was applied to the entire titration period. Costs included
published drug wholesale acquisition costs (WAC) in 2010 US dollars. Incremental
cost per QALY and incremental cost per responder were estimated for GXR com-
pared to ATX. Various one-way sensitivity analyses (SA) were conducted to exam-
ine the robustness of the model. RESULTS: Despite the lower WAC unit price, GXR
had an incremental cost of $171 over ATX because more GXR patients achieved
response and continued treatment. In the base case, the cost/QALY was $24,688
and the incremental cost per responder was $1,979. Most scenarios in the one-way
SA resulted in a cost/QALY below $50,000, with the exceptions of increasing GXR or
decreasing ATX costs by 25%. CONCLUSIONS: Compared to ATX, GXR is cost-effec-
tive, at the cost that is lower than the socially acceptable willingness-to-pay
threshold of $50,000/QALY, for the treatment of ADHD in children and adolescents.
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ECONOMIC IMPLICATIONS OF THE EFFECT OF LURASIDONE VERSUS OTHER
SELECTED ATYPICAL ANTIPSYCHOTICS ON CARDIOMETABOLIC PARAMETERS
IN PATIENTS WITH SCHIZOPHRENIA
Guo S1, Hernandez L1, Green J1, Sarocco P2
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OBJECTIVES: A cost-consequence analysis was performed to assess the economic
implications of changes in cardiometabolic parameters after six-week treatment
with lurasidone vs. other selected atypical antipsychotics in patients with
schizophrenia.METHODS:Amodel using discrete event simulationwas developed
to assess the economic impact from a US payer perspective over a two-year time-
frame. It uses baseline patient-level profiles from lurasidone trials to simulate
changes in cardiometabolic parameters (e.g., LDL, HDL, triglycerides, total choles-
terol, fasting glucose (FG), and BMI) associated with each treatment over six-weeks
using data from lurasidone clinical trials for lurasidone and olanzapine and from
the literature for risperidone, quetiapine IR and XR. Based on the simulations, the
model projects the number of cases requiring pharmacological treatment for hy-
perlipidemia (i.e., LDL130 mg/dL), hyperglycemia (i.e., FG 100-126 mg/DL), as well
as diabetes and cardiovascular events (CVD) using risk equations from the
Framingham Heart Study. Costs (in 2010 values) are accrued according to each
patient’s specific experience with treatments and events over the course of the
simulation. RESULTS: Per 1,000 treated patients, lurasidone is predicted to result in
47, 14, 16, and 2 fewer incident diabetes; 74, 56, 56, and 49 fewer hyperlipidemia
cases; and 191, 82, 82, and 16 fewer hyperglycemia cases than olanzapine, risperi-
done, quetiapine IR, and quetiapine XR, respectively. CVD events are also fewer
with lurasidone, but the differences among treatments areminimal. These clinical
benefits would result in net savings of $857, $414, $431, and $147 per patient,
respectively, and $5,803, $8,657, $9,753, and $7,647 per patient, respectively, if in-
cluding the costs of antipsychotic treatment. CONCLUSIONS: Based on the results
of these economic analyses, lurasidone represents a potentially cost-saving alter-
native for the treatment of patients with schizophrenia.
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COST-EFFECTIVENESS OF ANTIDEPRESSANT THERAPIES IN KOREA
Shin S, Jung SY, Song H, Park J, Ahn J
National Evidence-based Healthcare Collaborating Agency (NECA), Seoul, South Korea
OBJECTIVES: To assess cost effectiveness (CE) of antidepressant (AD) therapy, an-
tidepressantswere grouped as tricyclic antidepressants (TCAs), selective serotonin
reuptake inhibitors (SSRIs), and new antidepressants (NADs; SNRIs and others) and
a CEmodel, reflecting relationship between adherence and relapse among patients
with depression in Korea, was developed. METHODS: Effectiveness and cost pa-
rameters were estimated using the KoreanHealth Insurance Review&Assessment
Service (HIRA) claim database (2006-2008). Subjects were selected by age of 18-84,
without a prior history ofmedical visit due to depressionwithin 6-month pre-index
period and with at least 3 psychiatric visits within 3-month post-index period. A
decision-tree model comparing the three ADs groups captured rate of patient ad-
herence, rate and frequency of relapse with/without requiring hospitalization and
healthcare resource utilization associated costs. Adherence was defined as over
75% of Medication Possession Ratio (MPR) in 3-month pre-index period. Costs were
estimated with healthcare system perspective excluding unobservable out-of-
pocket payment (in 2010 KRW). Primary outcome was proportion of patients with
relapse by adherence or nonadherence. RESULTS: The adherence rate was 16.17%
in TCAs, 32.57% in SSRIs, and 34.18% in NADs. The proportions of patients experi-
encing a relapse requiring hospitalization 3.48%, 1.79%, 2.93%, for TCAs, SSRIs,
NADs while the proportion of patients with a relapse not requiring hospitalization
were 33.26%, 13.23%%, 12.59%, respectively. The expected cost of TCAs was
341,187KRW, SSRIs 415,282KRW, NADs 452,586KRW, and expected probabilities to
prevent relapse was 69.9% in TCAs, 76.6% in SSRIs, 74.8% in NADs. The result of
cost-effectiveness analysis was SSRIs is the most cost-effectiveness AD group
(ICER: 1,102,548KRW per relapse prevented). These findings were supported by
sensitivity analysisCONCLUSIONS: The use of SSRIs for treatmentwith depression
in Korean healthcare setting is predicted in this model to results in better clinical
outcomes and lower total healthcare costs over than its comparators.
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FUMARATE EXTENDED-RELEASE IN PATIENTS WITH MAJOR DEPRESSIVE
DISORDER WITH AN INADEQUATE RESPONSE TO PREVIOUS THERAPY
Svedsater H1, Locklear J2, Johal S3, Stillman IO4
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OBJECTIVES:Major depressive disorder (MDD) is estimated to affect 3.4% of the US
population. The goal of MDD treatment is remission. We determined the cost-
effectiveness (CE) of adjunct quetiapine fumarate extended-release (QTP XR) ver-
sus adjunct aripiprazole ([ARP] 15 mg/d), and budget impact of adjunct QTP XR in
MDD patients with an inadequate response to previous antidepressant therapy.
METHODS: The CE model used a Markov process to model outcomes in 2nd- and
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3rd-line therapy, analyzed from a third-party US payer perspective. Efficacy pa-
rameters included placebo-adjusted absolute weekly rates of remission and re-
sponse, taken from MDD treatment trials. Continuation, add-on, switch, and dis-
continuation rates, and inpatient and outpatient costs, were derived from the
PharMetrics database (Jan 2003–Mar 2008). Pharmacy costs were based on Whole-
sale Acquisition Costs. A budget impact model determined annual health care
costs of adding adjunct QTP XR to a formulary assuming a population of 185,000
patients,with 1.2%being treated forMDD.RESULTS:Adjunct QTPXR (300mg/d, but
not 150 mg/d) reduced total costs per remitting patient: $1998 versus adjunct ARP
when used in 2nd-line therapy ($17,168 vs $19,166) and $2608 in 3rd-line therapy
($22,051 vs $24,659). Themain drivers ofmodel outcomeswere pharmacy costs and
clinical efficacy. Probabilistic sensitivity analyses suggest model outcomes were
generally stable to varying assumptions. Increasing QTP XR use from 3.6% to 4.6%,
assuming a reduction in the use of other MDD treatments, increased overall health
care costs by 0.5% ($10,851,702–$10,909,591), with pharmacy costs rising by 2.3%
($3,006,169–$3,076,594). CONCLUSIONS: QTP XR (300 mg/d) as adjunct therapy, in
patients with MDD who previously have had an inadequate response to 1st- or
2nd-line therapy,was cost-effective in achieving remission comparedwith adjunct
ARP (15mg/d). Increasing QTP XR use as 2nd- or 3rd-line therapy had a limited and
well-defined budget impact. Supported by AstraZeneca Pharmaceuticals LP, Wil-
mington, Delaware.
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ECONOMIC EVALUATION OF DESVENLAFAXINE IN THE ACUTE MANAGEMENT
OF INPATIENTS WITH MAJOR DEPRESSIVE DISORDER FROM A BRAZILIAN
PUBLIC HOSPITAL PERSPECTIVE
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OBJECTIVES: In 2009, 8,211 hospitalizations for major depressive disorder (MDD)
occurred in Brazilian public hospitals, withmean duration of 20.5 days and average
cost of 770BRL. To inform decision-makers about more efficient therapeutic strat-
egies, this study aimed to compare costs of desvenlafaxine, escitalopram and du-
loxetine in the treatment of MDD inpatients from Brazilian public hospital
perspective.METHODS: A decision tree model was built to assess costs of desven-
lafaxine 50 mg/d, escitalopram 10 mg/d and duloxetine 60 mg/d to treat inpatients
admitted due to MDD. Four health states were considered: remission, dose escala-
tion due to lack of response, switching to another antidepressant after discontin-
uation caused by adverse event or failure, and treatment failure. This assessment
assumes similar efficacy among alternatives due to lack of head-to-head clinical
trials. Cost estimation assumed an 8-week time horizon. Relative risk of dropout
versus placebo was obtained through systematic review. Only direct medical costs
were considered and the cost components were drug acquisition costs and daily
room charges. One-way sensitivity analyses were performed using drug prices,
proportion of duloxetine patients requiring drug titration, and daily room charges
(20%) as key variables. RESULTS: Desvenlafaxine avoided 12% of estimated drop-
outs compared to competing alternatives. The estimated treatment costs were
1,955BRL, 2,213BRL and 2,476BRL per patient treated with desvenlafaxine, escita-
lopram and duloxetine, respectively. Therefore, desvenlafaxine exhibited savings
of257BRL and520BRL versus escitalopram and duloxetine, respectively.Within
sensitivity analyses, the lower saving was observed when duloxetine titration was
set as 0% (94BRL versus escitalopram) and the higher when a20% variation was
applied to daily room charges (-580BRL versus duloxetine). CONCLUSIONS: Des-
venlafaxine would be a cost-saving strategy compared to escitalopram and dulox-
etine in the treatment of patients admitted to the hospital due to MDD, given its
lower price and lower dropout rates as a consequence of side effects.
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OF ASSOCIATED MAJOR DEPRESSIVE DISORDER IN MEDICALLY ILL INPATIENTS
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OBJECTIVES: Depression symptoms in medically ill patients are known to ad-
versely impact treatment compliance, healthcare costs and outcomes. Thus, this
study aims to compare costs of desvenlafaxine, escitalopram and duloxetine in
medically ill inpatients with associated major depressive disorder (MDD) from the
Brazilian public general hospital perspective. METHODS: A decision-tree model
was built to assess costs of desvenlafaxine 50 mg/d, escitalopram 10 mg/d and
duloxetine 60 mg/d to treat patients with MDD in Brazilian public hospitals. Four
health states were considered: remission, dose escalation due to lack of response,
switching to another antidepressant after discontinuation caused by adverse
event, and treatment failure. Assessment assumed similar efficacy among alter-
natives due to lack of head-to-head clinical trials. Cost estimation assumed an
8-week time horizon. Relative risk of dropouts compared to placebo was obtained
through literature systematic review. Since the model assumed that hospitaliza-
tion are not due to MDD, only drug acquisition costs were considered in the base
case. Unit costs were: 3.09BRL, 4.04BRL and 6.91BRL for desvenlafaxine, escitalo-
pram and duloxetine, respectively. Official prices were obtained from 2010 CMED/
ANVISA list. One-way sensitivity analyses were performed using drug prices and
proportion of duloxetine patients requiring drug titration as key variables.
RESULTS: Desvenlafaxine avoided 12% of estimated dropouts compared to com-
peting alternatives. The estimated treatment costs were 144BRL, 250BRL and
364BRL per patient treated with desvenlafaxine, escitalopram and duloxetine, re-
spectively. Therefore, desvenlafaxine exhibited savings of 106BRL and 220BRL
versus escitalopram and duloxetine, respectively. Within the sensitivity analyses,
the lower and higher savings were observed when Brazilian public procurement
priceswere adopted (82BRL versus escitalopramand216BRL versus duloxetine).
CONCLUSIONS: Desvenlafaxine would be a cost-saving strategy compared to esci-
talopram and duloxetine in medically ill inpatients treated for MDD, due its lower
price and lower dropout rates as a consequence of side effects.
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ECONOMIC IMPACT OF CYP450 PHARMACOGENETIC TESTING ON DEPRESSION
TREATMENT
Syeda SS, Wu WK
St. John’s University, Jamaica, NY, USA
OBJECTIVES: CYP450 enzyme activities have been associated with inter-individual
variability affecting efficacy and tolerability among non-psychotic major depres-
sive disorder (MDD) patients. Pre-prescription pharmacogenetic testing helps to
identify patients with increased risk for adverse reactions, lack of efficacy and
increased hospitalization costs. These test results could assist doctors to prescribe
alternative therapy or optimum doses. Present study is to estimate the cost effec-
tiveness of pre-prescription pharmacogenetic testing to assess the CYP450 enzyme
activity for the treatment of depression using selective serotonin reuptake inhibi-
tors (SSRIs).METHODS:Markov model was developed from societal perspective to
identify cost and quality adjusted lifemonths (QALM) gained for carrying out phar-
macogenetic testing compared to no test strategy. A systematic search of the liter-
ature was carried out to identify published evidence for associations between ad-
verse events, dropout rates and the three phenotypic groups: ultrafast
metabolizers, poor metabolizers and intermediate metabolizers. Potentially rele-
vant papers were used to derive the transitional probabilities, costs and sensitivity
as well as specificity of CYP450 enzyme testing technique. Multiple one-way sen-
sitivity analyses were performed to find the robustness of the model. RESULTS:
Projected outcomes associated with pre-prescription CYP450 testing strategy for a
patient with MDD was $4367/6.5 compared to $5634/6.4 QALM in no test strategy.
The testing strategywas found to be dominant between the above two options. The
model was found to be sensitive to utility values, cost of adverse events follow up,
percentage of ADRdropouts and remission rates.CONCLUSIONS:The study results
indicate that CYP450 genotype-guided SSRI treatment for depression is potentially
cost saving and leads to improved quality of life in patients. Yet the model is not
robust with respect to selected clinical and economic variables. Further studies
should be pursued to confirm the value of genotype-guided therapy before broadly
applying in the regular clinical practice
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PHYSICAL AND MENTAL HEALTH AS IMPORTANT INPUTS INTO WAGE
FUNCTION
Ghushchyan VH, Campbell JD, Libby AM
University of Colorado, Denver, Aurora, CO, USA
OBJECTIVES: Human capital theory posits that education, experience and health
are the main contributors to the value of labor, measured as individual wage or
earnings. We quantified the effects of general physical and mental health on an-
nual wage and possible inefficiencies in reaching the wage frontier for a U.S. rep-
resentative population.METHODS:Weutilized theMedical Expenditure Panel Sur-
vey for 2000-2007 for individual economic and health measures and population
estimates. General health wasmeasured using validated instruments (SF-12 phys-
ical and mental scores). Annual wage was expressed in 2009 US dollars. Stochastic
frontier regression was used to estimate the impact of physical and mental health
on annual wage. The model estimated wage function and individual level ineffi-
ciency. Specifically, annual wage wasmodeled as a function of years of experience
and educational attainment, plus physical and mental health, controlling for gen-
der, race/ethnicity, and region. Sensitivity analyseswere conducted to examine the
impact of varying assumptions on the results. RESULTS: A one percent increase in
physical health status resulted in 0.32% (0.27% - 0.36%) increase of annualwage and
one percent increase in mental health status resulted in 0.13% (0.09% - 0.16%)
increase of annual wage. The summative elasticity of these two health factors is
greater than the elasticity of experience: 0.38% (0.36% - 0.39%). In addition better
physical and mental health are associated with higher productivity and smaller
variations of inefficacy and stochastic error variance. CONCLUSIONS: General
physical and mental health make significant contributions to human capital as
reflected in wages in the U.S., as well as in expected productivity gains. Deficits in
human health are estimated to leave potential productivity gains unrealized. The
relativemagnitude of the health effect compared to the experience effect supports
larger investments in access to health care.
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MEASURES OF MEDICATION ADHERENCE IN ORAL VERSUS LONG-ACTING
RISPERIDONE IN TEXAS MEDICAID PATIENTS WITH SCHIZOPHRENIA
Kim DN, Park H, Rascati KL
University of Texas at Austin, Austin, TX, USA
OBJECTIVES: Medication adherence has been shown to be an important factor in
preventing schizophrenia-related relapses, and long-acting injectable risperidone
has been shown to be effective in improving medication adherence. The objective
of this study was to determine the medication adherence rates of schizophrenic
patients treatedwith either oral risperidone only (oral cohort) or long-acting inject-
able risperidone/ oral risperidone (injectable cohort).METHODS: Texas Medic-
aid prescription claims data (January 2006 to December 2008) were analyzed for
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